Background: The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). Findings from final overall survival (OS) analysis and assessment of post-study treatment impact are presented.
introduction Lung cancer remains the most common cancer and the leading cause of cancer death, worldwide and in China [1, 2] . Standard chemotherapy has reached a therapeutic plateau in the treatment of advanced non-small-cell lung cancer (NSCLC) with patients progressing within 3-6 months and overall survival (OS) not extending beyond 10 months [3, 4] . The need for more effective treatment has spurred the ongoing development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Erlotinib and gefitinib are first-generation EGFRTKIs approved as second-and third-line advanced NSCLC treatments, with dramatic responses in patients with sensitising EGFR mutations.
Seven trials have investigated first-line erlotinib or gefitinib in EGFR mutation-positive advanced NSCLC and have demonstrated significantly longer progression-free survival (PFS) with first-generation EGFR-TKIs compared with chemotherapy [5] [6] [7] [8] [9] [10] [11] . The gefitinib trials are completed and none reported a corresponding significant difference in OS [10, [12] [13] [14] , emphasising the impact of post-study treatment crossover on survival, while OS benefit with first-line erlotinib remains unknown. The LUX-Lung trials have shown that the second-generation EGFR-TKI afatinib can achieve significant OS improvement compared with chemotherapy in patients with EGFR exon 19 deletion, but not in those with exon 21 L858R mutation [15] . It remains unclear whether first-line erlotinib produces similar OS differences in these sub-populations.
The OPTIMAL study was the first phase III, randomised, open-label study to compare first-line erlotinib with gemcitabine plus carboplatin in EGFR mutation-positive advanced NSCLC patients [7] . Erlotinib achieved significantly longer PFS compared with chemotherapy (13.1 versus 4.6 months; P < 0.0001) [7] and significantly improved quality of life (QoL) [16] . Early OS analysis data were presented in 2012 [17] . We report findings from the final OS analysis and post hoc assessment of post-study treatment impact on OS.
materials and methods

study design and treatment
Full details of the OPTIMAL study, conducted at 22 centres in China, have been published previously [7] . Eligible patients were over 18 years old, had histologically confirmed advanced or recurrent stage IIIB/IV NSCLC with confirmed activating EGFR mutation (exon 19 deletion or exon 21 L858R mutation) and had not received prior systemic anticancer therapy. Patients were randomised 1:1 to oral erlotinib 150 mg daily until disease progression or unacceptable toxicity, or up to four cycles of chemotherapy [i.v. gemcitabine 1000 mg/m 2 on days 1 and 8 and carboplatin (area under the curve = 5.0) i.v. on day 1 of a 3-week cycle]. The primary end point was PFS. Secondary end points included OS (time from randomisation to death), objective response rate, time to progression, duration of response, safety and QoL. Efficacy was assessed every 6 weeks until disease progression and every 3 months after disease progression for 2 years or until death. Post-study treatments, which were provided at the physicians' discretion, were assessed retrospectively.
The study was carried out in accordance with Good Clinical Practice and the principles of the Declaration of Helsinki. The protocol was approved by local ethics committee at participating centres. All patients provided written informed consent.
statistical analysis
Final OS analysis was planned for when 70% of deaths had occurred in the intent-to-treat population. Survival was estimated with Kaplan-Meier methodology and summarised as a median value with range and a two-sided 95% confidence interval (CI). All analyses were conducted by two-sided log-rank test and evaluated at a two-sided 5% significance level. Treatment effect estimates were expressed as hazard ratios (HRs) for erlotinib versus chemotherapy with a two-sided 95% CI. Subgroup OS analyses were carried out with a Cox proportional hazards model and included randomisation stratification factors. All analyses were conducted using SAS version 9.1.3.
results
patients
Of the 165 randomised patients, 154 had measurable disease and received at least one dose of study drug (82 erlotinib, 72 Table 1 . More patients in the erlotinib arm versus the chemotherapy arm did not receive any treatment following discontinuation of study drug (36.6% versus 22.2%). Post-study treatment imbalance between arms was also reflected in the EGFR exon 19 deletion subgroup but was balanced between arms in the exon 
overall survival
Median follow-up for OS was 25.9 months. Events for OS analysis were met at the data cut-off of 21 December 2012; 68 and 52 deaths occurred in the erlotinib and chemotherapy arms, respectively. In the overall population, median OS was similar between the erlotinib and chemotherapy arms (22.8 and 27.2 months, respectively) with no significant between-group difference (HR, 1.19; 95% CI 0.83-1.71; P = 0.2663; Figure 1) . None of the clinical characteristics, including EGFR mutation subtype, had significant impact on OS between treatment arms (Figure 2 ).
Patients with EGFR exon 19 deletions in the erlotinib arm, over 40% of whom did not receive post-study treatment, had slightly shorter OS than those in the chemotherapy arm, among whom only 12.8% did not receive post-study treatment; however, the difference was not significant (27.0 versus 31.5 months; P = 0.1037; Table 2 ). Conversely, OS was slightly longer in patients with EGFR exon 21 L858R mutations in the erlotinib arm than those in the chemotherapy arm (21.5 versus 18.3 months; P = 0.7392; Table 2 ). It is important to note that post-study treatment was balanced between treatment arms in patients with exon 21 L858R mutations but was imbalanced in patients with exon 19 deletions.
impact of post-study therapy on OS
In the overall population, patients who received sequential therapy of EGFR-TKI and chemotherapy throughout the course of treatment had significantly improved OS compared with those who received either EGFR-TKI or chemotherapy only (29.7 versus 20.7 and 11.2 months, respectively; P < 0.0001; Figure 3 ). In the erlotinib arm, OS was significantly longer in patients who subsequently received chemotherapy (28.0 months) or any other therapy compared with those who did not receive poststudy treatment (P = 0.0077; Table 2 ). In the chemotherapy arm, patients who received a subsequent EGFR-TKI had significantly improved OS compared with those who received a non-EGFR-TKI-containing regimen and those who did not receive post-study treatment (32.0 versus 14.3 and 11.2 months, respectively; P < 0.0001).
discussion
To our knowledge, OPTIMAL is the first phase III study to report final OS analysis of erlotinib versus chemotherapy as first-line therapy in EGFR mutation-positive advanced NSCLC. Erlotinib showed similar OS with chemotherapy with no significant difference in the overall population or by EGFR mutation subtype. The erlotinib-associated PFS benefits reported previously in the overall population and EGFR mutation subgroups did not translate into significant OS benefits. The imbalance in post-study treatments between treatment arms in the overall population and in the exon 19 deletion subpopulation is likely to have confounded the true survival benefit of initial treatment.
Our findings are consistent with completed phase III studies of first-line gefitinib versus chemotherapy, which reported no significant difference in OS between arms irrespective of EGFR mutation status, despite achieving PFS benefit with gefitinib [5, 8, [10] [11] [12] [13] [14] . Similar findings were reported from the interim analysis (data cut-off 24 January 2013) of the ongoing EURTAC trial of erlotinib versus chemotherapy [6, 18] , suggesting that post-study treatment has critical impact on OS. This study further reveals important effect of post-study treatments on OS and suggests that EGFR-TKI makes the biggest contribution to the outcome of patients with positive EGFR mutations, and EGFR mutant patients who received chemotherapy only had the shortest OS (Figure 3) .
A recent unplanned pooled analysis of the LUX-Lung 3 [19] and LUX-Lung 6 [20] studies, which compared first-line afatinib versus chemotherapy, showed improved OS with afatinib in the overall population of patients with tumours harbouring common EGFR mutations, demonstrating a median OS of 27.3 months with afatinib and 24.3 months with chemotherapy (P = 0.037) [15] . These findings should be interpreted cautiously as the crossover rate from chemotherapy to EGFR-TKI at progression was substantially lower (66%) [15] compared with other first-line trials, which have reported crossover rates of up to 96% [6, 13] . As individual trials, significant OS improvement with afatinib versus chemotherapy was not demonstrated in the overall population in either LUX-Lung 3 (28.2 months in both arms; P = 0.39) [19] or LUX-Lung 6 (23.1 versus 23.5 months; P = 0.61) [20] . A meta-analysis of phase III trials comparing first-line gefitinib, erlotinib or afatinib with chemotherapy showed no evidence that EGFR-TKI improved OS, despite showing improved PFS, with no difference observed between EGFR-TKIs [21] .
Post-study treatments may confound the true effect of firstline treatment on OS. In the current study, ∼40% of erlotinibtreated patients in the overall population and exon 19 deletion subpopulation did not receive any post-study treatment. On the other hand, almost 80% of patients who received first-line chemotherapy received subsequent treatment, with 69% of patients eventually receiving an EGFR-TKI. Crossover has become increasingly frequent; ∼50% of patients in the IPASS study (cut-off date June 2010) who received first-line chemotherapy received subsequent EGFR-TKI, while 96% of patients in the NEJ002 study (cut-off date December 2010) who received first-line chemotherapy went on to receive subsequent EGFR-TKI therapy [12, 13] . Patients in the pooled LUX-Lung analysis with EGFR exon 19 deletions had improved OS with afatinib compared with chemotherapy (31.7 versus 20.7 months; P = 0.0001), while OS was similar between treatment arms in patients with EGFR exon 21 L858R mutation [15] . Among patients with EGFR exon 19 deletions in our study, treatment crossover was considerably more frequent in the chemotherapy arm than the erlotinib arm. Similar to the WJTOG and NEJ002 studies [13, 14] , the imbalance in crossover rates and high proportion of EGFR-TKI-treated patients who did not receive poststudy treatment compared with chemotherapy-treated patients may explain the discrepancy between OS outcomes in the current study and the LUX-Lung studies.
To adjust for the confounding effect of treatment crossover, an exploratory analysis of the EURTAC study that was controlled for second-line post-study therapy and demonstrated a trend towards improved OS for erlotinib compared with chemotherapy [22] , emphasising the true, non-confounded contribution of erlotinib to prolonged survival. When OS was censored at the time of second-line treatment initiation (to evaluate OS only when patients were not receiving second-line treatment), the HR was 0.68 (95% CI 0.37-1.25, P = 0.21; median OS was not reached with erlotinib versus 20.8 months with chemotherapy). When a marginal structural model was used to account for pre-and post-progression crossover, HR was 0.70 (95% CI 0.27-1.78; P = 0.45) with a median OS of 22.9 months with erlotinib and 16.5 months with chemotherapy [22] .
In this study, patients who received post-study treatment had significantly improved OS compared with those who did not, suggesting that patients should continue treatment beyond first-line therapy. Patients who received an EGFR-TKI throughout their treatment course had longer OS compared with those who did not, while patients who only received chemotherapy had the shortest OS, emphasising the impact of post-study treatment on OS and the important contribution of EGFR-TKI to prolonged survival. Although definitive conclusions cannot be made from this post hoc analysis, these findings emphasise the importance of understanding effects of therapies on tumour evolution to optimise the sequence of chemotherapy and EGFR-TKI for maximum survival benefit. In addition to post-study therapy, factors other than disease progression, such as QoL, may be important in improving survival.
In summary, erlotinib-related benefits for PFS were not observed for OS, probably due to the confounding effects of post-study therapies. Patients who received both EGFR-TKI and chemotherapy throughout their treatment course achieved prolonged OS compared with those who did not. Significant OS benefits in patients who received EGFR-TKIs demonstrated its important role in prolonging survival and suggest that erlotinib should be considered a standard first-line treatment of NSCLC patients with EGFR mutation and EGFR-TKI treatment following first-line therapy (beyond progression) also brings significant benefits to those patients.
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